Elderly patient with complex concomitant cardiovascular disease

Elderly patient with complex concomitant cardiovascular disease

The clinical case we present shows that an inadequate pharmacological treatment of type 2 diabetes does not prevent complications affecting especially the cardiovascular system. Cardiovascular events remain the leading cause of death in people with diabetes. The optimal management of the patient de...

Full description

Bibliographic Details
Main Authors:	Vincenzo Cimino, Cristina Albrici, Angela Ida Pincelli, Damiano Calella, Silvia Galliani, Francesca Pesenti, Mario Perotti
Format:	Article
Language:	English
Published:	AboutScience Srl 2018-08-01
Series:	AboutOpen
Subjects:	Type 2 diabetes Cardiovascular risk Empagliflozin
Online Access:	https://journals.aboutscience.eu/index.php/aboutopen/article/view/151

Similar Items

Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial
by: Subodh Verma, et al.
Published: (2021-08-01)

Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial
by: Antonio Ceriello, et al.
Published: (2020-10-01)

A NEW INDICATION FOR EMPAGLIFLOZIN: TURNING POINT IN THE TREATMENT OF TYPE 2 DIABETES
by: M. V. Amosova, et al.
Published: (2017-12-01)

Cardiovascular death risk reduction in type 2 diabetes patients with confirmed cardiovascular diseases
by: Е. V. Shlyakhto, et al.
Published: (2018-09-01)

Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo‐controlled double‐blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi‐center placebo‐controlled double‐blind randomized trial
by: Atsushi Tanaka, et al.
Published: (2020-11-01)

Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes
by: Schernthaner G, et al.
Published: (2017-01-01)

New tendencies in the treatment of diabetic and cardiovascular diseases: a view of cardiologists
by: I. Z Bondarenko, et al.
Published: (2018-06-01)

Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
by: Mafalda Ramos, et al.
Published: (2021-08-01)

Obese and hypertensive elderly patient, with incipient diabetic nephropathy and previous cardiovascular event, long-term treated with secretagogues
by: Andrea Da Porto
Published: (2018-07-01)

Overweight elderly patient suffering from multiple comorbidities
by: Sebastiano Bruno Solerte
Published: (2018-07-01)

Does Empagliflozin Modulate Leukocyte–Endothelium Interactions, Oxidative Stress, and Inflammation in Type 2 Diabetes?
by: Francisco Canet, et al.
Published: (2021-07-01)

Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial
by: João Pedro Ferreira, et al.
Published: (2020-11-01)

La gestione del paziente diabetico tra presente e futuro
by: Angelo Avogaro, et al.
Published: (2017-10-01)

Cost-effectiveness analysis of empagliflozin in the treatment of patients with type 2 diabetes and established cardiovascular disease in Italy, based on the results of the EMPA-REG OUTCOME study
by: Sergio Iannazzo, et al.
Published: (2017-10-01)

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME® trial
by: Takashi Kadowaki, et al.
Published: (2019-05-01)

SGLT2 inhibitors in T2D and associated comorbidities — differentiating within the class
by: Guntram Schernthaner, et al.
Published: (2019-06-01)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
by: Santos Cavaiola T, et al.
Published: (2018-04-01)

Metformin + Sodium-glucose Co-transporter-2 Inhibitor: Salutogenic Lifestyle Mimetics in a Tablet?
by: Sanjay Kalra, et al.
Published: (2018-01-01)

THE INTERIM EXPERTS’ COUNCIL RESOLUTION ON THE EMPA-REG OUTCOME TRIAL ISSUES
by: M. V. Shestakova, et al.
Published: (2016-05-01)

Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond
by: Elif A Oral
Published: (2016-09-01)

Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial
by: Atsushi Tanaka, et al.
Published: (2021-06-01)

Patient not adequately controlled with insulin therapy and hospitalized for congestive heart failure
by: Vera Frison, et al.
Published: (2018-08-01)

Diabetes onset before age 40: more and more often it is type 2 diabetes
by: Viola Sanga
Published: (2018-09-01)

Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure
by: Luis M. Pérez-Belmonte, et al.
Published: (2021-08-01)

Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?
by: Ampudia-Blasco FJ, et al.
Published: (2017-01-01)

Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial
by: Andrea Natali, et al.
Published: (2017-10-01)

Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus
by: Mojca Lunder, et al.
Published: (2018-12-01)

An overlooked diabetes in a relatively young patient
by: Sandro Inchiostro
Published: (2018-07-01)

Long-term efficacy and safety of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes in Indian subgroup: Results from a 76-week extension trial of phase iii, double-blind, randomized study
by: Sunil Gupta, et al.
Published: (2017-01-01)

Control of cardiovascular risk in patients with diabetes
by: Zhernakova Yu.V., et al.
Published: (2016-08-01)

Control of cardiovascular risk in patients with diabetes
by: Yu V Zhernakova, et al.
Published: (2016-09-01)

Empagliflozin and the Prevention of Heart Failure
by: Douglas L. Mann, MD, et al.
Published: (2017-08-01)

Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus
by: Vladimir V. Salukhov, et al.
Published: (2016-12-01)

Sodium glucose cotransporter 2 inhibitors as diuretic adjuvants in acute decompensated heart failure: a case series
by: Matthew Griffin, et al.
Published: (2020-08-01)

SGLT2 inhibitors and the changing landscape for treatment of diabetes
by: Liu S, et al.
Published: (2019-07-01)

Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study
by: Hirotatsu Nakaguchi, et al.
Published: (2020-11-01)

A patient who does not like insulin
by: Paola Ubaldi
Published: (2018-09-01)

SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in <i>db/db</i> Mice, a Model of Type 2 Diabetes
by: Anton I. Korbut, et al.
Published: (2020-04-01)

Empagliflozin in type 1 diabetes
by: Mathieu C, et al.
Published: (2019-08-01)

Impact of SGLT2i on cardiovascular outcomes and heart failure in patients with type 2 diabetes
by: Juan José Rodríguez, et al.
Published: (2018-01-01)